BridgeBio Pharma (BBIO) Competitors $36.85 +0.04 (+0.11%) Closing price 04:00 PM EasternExtended Trading$36.68 -0.16 (-0.45%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends BBIO vs. ONC, TEVA, SMMT, GMAB, ITCI, VTRS, MRNA, RDY, PCVX, and SRPTShould you be buying BridgeBio Pharma stock or one of its competitors? The main competitors of BridgeBio Pharma include Beigene (ONC), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Intra-Cellular Therapies (ITCI), Viatris (VTRS), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry. BridgeBio Pharma vs. Beigene Teva Pharmaceutical Industries Summit Therapeutics Genmab A/S Intra-Cellular Therapies Viatris Moderna Dr. Reddy's Laboratories Vaxcyte Sarepta Therapeutics Beigene (NASDAQ:ONC) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, community ranking, media sentiment and dividends. Does the MarketBeat Community favor ONC or BBIO? BridgeBio Pharma received 173 more outperform votes than Beigene when rated by MarketBeat users. CompanyUnderperformOutperformBeigeneN/AN/ABridgeBio PharmaOutperform Votes17371.78% Underperform Votes6828.22% Do analysts recommend ONC or BBIO? BridgeBio Pharma has a consensus price target of $51.67, suggesting a potential upside of 40.21%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts clearly believe BridgeBio Pharma is more favorable than Beigene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beigene 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00BridgeBio Pharma 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.92 Is ONC or BBIO more profitable? Beigene has a net margin of -25.94% compared to BridgeBio Pharma's net margin of -201.53%. BridgeBio Pharma's return on equity of 0.00% beat Beigene's return on equity.Company Net Margins Return on Equity Return on Assets Beigene-25.94% -25.12% -14.95% BridgeBio Pharma -201.53%N/A -74.34% Do institutionals and insiders hold more shares of ONC or BBIO? 48.6% of Beigene shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 7.4% of Beigene shares are owned by company insiders. Comparatively, 24.7% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has higher valuation and earnings, ONC or BBIO? BridgeBio Pharma has lower revenue, but higher earnings than Beigene. Beigene is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeigene$2.46B10.16-$881.71M-$8.24-30.99BridgeBio Pharma$9.30M748.85-$643.20M-$2.41-15.29 Which has more risk and volatility, ONC or BBIO? Beigene has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Does the media favor ONC or BBIO? In the previous week, BridgeBio Pharma had 23 more articles in the media than Beigene. MarketBeat recorded 26 mentions for BridgeBio Pharma and 3 mentions for Beigene. Beigene's average media sentiment score of 0.37 beat BridgeBio Pharma's score of 0.32 indicating that Beigene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beigene 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Pharma 9 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryBridgeBio Pharma beats Beigene on 13 of the 17 factors compared between the two stocks. Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BBIO vs. The Competition Export to ExcelMetricBridgeBio PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.96B$7.05B$5.80B$8.94BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-15.296.0926.4118.84Price / Sales748.85314.10450.1476.68Price / CashN/A67.8344.0437.47Price / Book-4.776.757.634.64Net Income-$643.20M$138.11M$3.18B$245.69M7 Day Performance5.59%-1.99%-1.82%-2.59%1 Month Performance2.13%-1.51%0.22%-2.30%1 Year Performance7.87%-3.20%17.25%13.71% BridgeBio Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BBIOBridgeBio Pharma4.7193 of 5 stars$36.85+0.1%$51.67+40.2%+2.4%$6.96B$9.30M-15.29400Earnings ReportAnalyst ForecastInsider TradeNews CoverageGap UpONCBeigeneN/A$230.86+2.4%N/AN/A$22.56B$2.46B-28.0210,600Insider TradeNews CoverageGap UpTEVATeva Pharmaceutical Industries2.8879 of 5 stars$16.24-2.4%$23.57+45.2%+30.1%$18.39B$16.54B-11.2037,851SMMTSummit Therapeutics2.3035 of 5 stars$21.37-2.1%$33.57+57.1%+516.6%$15.76B$700,000.00-76.32110Gap UpGMABGenmab A/S4.5897 of 5 stars$21.30+1.8%$42.17+98.0%-22.5%$14.10B$2.39B20.682,204ITCIIntra-Cellular Therapies3.9113 of 5 stars$127.82-0.2%$103.62-18.9%+74.4%$13.59B$464.37M-146.92560Earnings ReportAnalyst ForecastNews CoverageVTRSViatris2.3252 of 5 stars$10.80flat$13.67+26.5%-16.5%$12.89B$15.43B-14.5938,000News CoverageMRNAModerna4.7389 of 5 stars$32.99+3.4%$66.89+102.8%-61.2%$12.70B$6.85B-5.675,600Analyst DowngradeOptions VolumeHigh Trading VolumeRDYDr. Reddy's Laboratories2.8624 of 5 stars$13.60-2.8%$17.00+25.0%-11.7%$11.35B$311.31B21.6527,048Gap DownPCVXVaxcyte2.5867 of 5 stars$84.00+0.2%$127.71+52.0%+11.3%$10.47BN/A-18.26160Insider TradePositive NewsSRPTSarepta Therapeutics4.4962 of 5 stars$107.95-1.4%$176.77+63.8%-20.4%$10.31B$1.24B86.361,314Upcoming Earnings Related Companies and Tools Related Companies Beigene Alternatives Teva Pharmaceutical Industries Alternatives Summit Therapeutics Alternatives Genmab A/S Alternatives Intra-Cellular Therapies Alternatives Viatris Alternatives Moderna Alternatives Dr. Reddy's Laboratories Alternatives Vaxcyte Alternatives Sarepta Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BBIO) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BBIO Stock Alerts